Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million (approximately 521.
Search results for "hyaluronidase"
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are raising expectations that...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they...
Subcutaneous Revolution: Alteogen and BD Showcase Large-Volume Biologic Delivery Solution
As the development of high-dose biologic therapies accelerates across the biopharmaceutical industry, innovative...
Alteogen to Present Subcutaneous ADC Formulation Research at International Forum in June
Alteogen announced on the 23rd that it will present research results regarding subcutaneous dosing for antibody-drug...
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous...
Alteogen Secures U.S. Patent Registration for Keytruda SC Formulation
Alteogen announced on the 12th that it has secured registration with the United States Patent and Trademark Office for...
1